As compared to Gilead’s drug Atripla that is leading the market, a drug from GlaxoSmithKline and its Japanese partner Shionogi has proved better. It is once daily drug and it went through a late-stage clinical trial.

It is expected that Dolutegravir will reach the market later in 2013 and it is from a novel class of drugs known as integrase inhibitors that fight HIV/AIDS by blocking the virus causing the disease from entering cells.

HIV/AIDS was an area that was dominated by the British group GSK but with US rival Gilead taking the lead, GSK will have to work out on it.

It is being thought that clinicians will get impressed by dolutegravir’s success against Gilead’s popular Atripla treatment and it was taken as a single tablet and as Gilead’s own new Quad pill, which also contains an integrase inhibitor, only matched Atripla.

In 2012 Atripla that enjoys the leading HIV/AIDS treatment in the United States made about $3.2 billion in sales and this is a huge profit.

John Pottage, MD, ViiV’s chief medical officer said, “This study represents an important milestone in the development of dolutegravir-based regimens, including a single-tablet regimen containing dolutegravir, abacavir and lamivudine, and also for the Shionogi-ViiV Healthcare joint venture.”